Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Show more

Location: 1111 Kane Concourse, Bay Harbor Islands, FL, 33154, United States | Website: https://www.avenuetx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.751M

52 Wk Range

$0.17 - $3.54

Previous Close

$0.58

Open

$0.55

Volume

3,434

Day Range

$0.55 - $0.55

Enterprise Value

-1.575M

Cash

3.326M

Avg Qtr Burn

-1.254M

Insider Ownership

18.41%

Institutional Own.

3.15%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.